By Colin Kellaher
Shares of IDEAYA Biosciences Inc. rose sharply in premarket trading on Monday after the precision-medicine oncology company reported a pair of advances for its lead compound darovasertib.
The South San Francisco, Calif., company said its Phase 2 study evaluating the combination of darovasertib and Pfizer Inc.’s cancer drug…
Read the full article here